CollPlant Biotechnologies (NASDAQ:CLGN) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

CollPlant Biotechnologies (NASDAQ:CLGN) announced its earnings results on Saturday, May 30th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01, Zacks reports. CollPlant Biotechnologies had a negative net margin of 683.68% and a negative return on equity of 218.81%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.46 million.

CollPlant Biotechnologies Price Performance

NASDAQ CLGN opened at $0.34 on Thursday. The business’s fifty day moving average is $0.38 and its 200-day moving average is $0.78. The stock has a market capitalization of $4.90 million, a price-to-earnings ratio of -0.23 and a beta of 1.60. CollPlant Biotechnologies has a one year low of $0.27 and a one year high of $3.23.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.